via University of Southampton
Scientists from the Antibody and Vaccine group at the University of Southampton have discovered a way to transform antibody drugs previously developed to treat autoimmunity into antibodies with powerful anti-cancer activity through a simple molecular “switch”.
This work, published in the journal Cancer Cell, focuses on a molecule called CD40 which is present on the surface of immune cells and controls both autoimmunity and cancer. In autoimmunity, CD40 is thought to be over-stimulated, increasing the chance of the immune system attacking healthy tissues; whereas in cancer, CD40 is believed to be under-stimulated, enabling tumour cells to evade the immune system. Targeting of CD40 with antibody drugs is ongoing in therapeutic interventions for both diseases.
Accordingly, antibody drugs have been developed to either activate (agonists) or suppress (antagonists) the CD40 immune pathway. Researchers at the Centre for Cancer Immunology in Southampton, led by Professors Mark Cragg and Martin Glennie now reveal that an antagonist CD40 antibody can be transformed into an agonist by simply modifying the “constant” domain of the antibody. The antagonist-turned agonist “trick” was shown for three different antagonists, being driven by the hinge part of the constant domain that controls the flexibility of the antibody. One of these antibodies, was shown to be a “super”-agonist that could stimulate the immune system and cure cancer more effectively in preclinical models than the best CD40-targeting antibody currently in clinical trial.
“Being able to toggle between an autoimmune drug and a cancer medicine with a simple switch is really exciting.” said Dr Xiaojie Yu, first author of the study. “We gained a deeper understanding of the mechanism through which CD40 becomes activated, and eagerly look forward to applying this technology to more drug candidates.”
“Our findings build on a history of CD40 research here in Southampton and were surprising and exciting in equal measure,” said Professor Mark Cragg, senior author of the study. “Taking an antibody that suppresses the immune system and turning it on its head, to activate the immune system for cancer through a relatively simple process is unprecedented. More than that, the same approach could be used for other immune targets and we look forward to seeing testing this in the near future”.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- TYME-18 Demonstrates Anti-Cancer Effect in New Preclinical Data Presented at AACR 2020on June 23, 2020 at 7:12 am
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclin ...
- New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Combination Therapy with BeyondSpring’s Plinabulinon June 23, 2020 at 5:00 am
The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model Triple I/O Combination to Be Administered to ...
- IIT-M study shows way to enhance cancer treatmenton June 23, 2020 at 2:45 am
Madras researchers have shown ways in which traditional cancer therapies can be made more effective. The research team studied reactive oxygen species (ROS), which are h ...
- New Data Show Theratechnologies’ SORT1+ Technology is Effective in Many Treatment-Resistant Cancerson June 22, 2020 at 7:25 pm
Theratechnologies Inc. (Theratechnologies) (TH.TO) (THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting ...
- Organoids can help provide new level of accuracy in prescribing anti-cancer therapieson June 22, 2020 at 7:22 pm
Precision medicine, using the power of the human genome to diagnose and treat patients, is about to get even more precise.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Bladder Cancer Advocacy Network (BCAN) Announces 2020 Bladder Cancer Research Innovation Awardeeon June 22, 2020 at 3:08 pm
Award Fuels Bladder Cancer Research Innovation San Francisco, CA (UroToday.com) --The Bladder Cancer Advocacy Network (BCAN) announced the recipient of its ...
- AACR: Attacking pancreatic cancer by thwarting its survival strategieson June 22, 2020 at 6:35 am
At this week’s virtual meeting of the American Association for Cancer Research (AACR), several research groups are presenting new therapeutic tactics aimed at interrupting survival pathways in ...
- Apigenin and Luteolin Modulate Microglial Activation Via Inhibition of STAT1-Induced CD40 Expressionon June 19, 2020 at 5:00 pm
1 Silver Child Development Center, Department of Psychiatry and Behavioral Medicine, College of Medicine, University of South Florida, Tampa, FL 33612, USA 2 Center Excellence in Aging and Brain ...
- Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Canceron June 17, 2020 at 2:20 am
New therapeutics targeting immune checkpoint proteins have significantly advanced treatment of non-small cell lung cancer (NSCLC), but protein level quantitation of drug targets presents a critical ...
- Global CD40 Ligand Market 2020 Share, Industry Size, Growth by Top Key Players, Future Trends, Types and Application and Forecast to 2026on June 11, 2020 at 6:13 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “CD40 Ligand Market” report ...